These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 19847281)

  • 1. Evaluation of some biochemical markers as prognostic factors in malignant lymphoma.
    Khalifa KA; Alkilani AA; Ismail H; Soliman MA
    J Egypt Natl Canc Inst; 2008 Mar; 20(1):47-54. PubMed ID: 19847281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated serum levels of soluble CD44 variant 6 are correlated with shorter survival in aggressive non-Hodgkin's lymphoma.
    Sasaki K; Niitsu N
    Eur J Haematol; 2000 Sep; 65(3):195-202. PubMed ID: 11007056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels and differential expression of CD44 in childhood leukemia and malignant lymphoma: correlation with prognostic criteria and survival.
    Taçyildiz N; Cavdar AO; Yavuz G; Gözdaşoglu S; Unal E; Ertem U; Duru F; Ikinciogullari A; Babacan E; Kuzu I; Cin S
    Pediatr Int; 2001 Aug; 43(4):354-60. PubMed ID: 11472578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High serum soluble CD44 is correlated with a poor outcome of aggressive non-Hodgkin's lymphoma.
    Niitsu N; Iijima K
    Leuk Res; 2002 Mar; 26(3):241-8. PubMed ID: 11792412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of TNF alpha and its p55 soluble receptor in malignant lymphomas.
    Warzocha K; Salles G; Bienvenu J; Barbier Y; Bastion Y; Doche C; Rieux C; Coiffier B
    Leukemia; 1997 Apr; 11 Suppl 3():441-3. PubMed ID: 9209418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Serum tumor necrosis factor-alpha levels in non-Hodgkin's lymphoma patients and its relationship to prognosis].
    Li D; Li G; Wang B
    Zhonghua Zhong Liu Za Zhi; 1997 Jul; 19(4):293-6. PubMed ID: 11038763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of soluble CD44 in patients with breast and colorectal carcinomas and non-Hodgkin's lymphoma.
    Lockhart MS; Waldner C; Mongini C; Gravisaco MJ; Casanova S; Alvarez E; Hajos S
    Oncol Rep; 1999; 6(5):1129-33. PubMed ID: 10425314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated serum levels of soluble CD44 can identify a subgroup of patients with early B-cell chronic lymphocytic leukemia who are at high risk of disease progression.
    Molica S; Vitelli G; Levato D; Giannarelli D; Gandolfo GM
    Cancer; 2001 Aug; 92(4):713-9. PubMed ID: 11550139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma.
    Legouffe E; Rodriguez C; Picot MC; Richard B; Klein B; Rossi JF; Commes T
    Leuk Lymphoma; 1998 Oct; 31(3-4):351-7. PubMed ID: 9869199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of cytokines and prevalence of autoantibodies in lymphoma patients and their prognostic value.
    Uskudar Teke H; Gulbas Z; Bal C
    J BUON; 2014; 19(1):191-7. PubMed ID: 24659663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas.
    Shah N; Cabanillas F; McIntyre B; Feng L; McLaughlin P; Rodriguez MA; Romaguera J; Younes A; Hagemeister FB; Kwak L; Fayad L
    Leuk Lymphoma; 2012 Jan; 53(1):50-6. PubMed ID: 21895545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood concentrations of tumor necrosis factor-alpha in malignant lymphomas and their decrease as a predictor of disease control in response to low-dose subcutaneous immunotherapy with interleukin-2.
    Lissoni P; Bolis S; Mandalà M; Viviani S; Pogliani E; Barni S
    Int J Biol Markers; 1999; 14(3):167-71. PubMed ID: 10569139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients.
    Warzocha K; Salles G; Bienvenu J; Bastion Y; Dumontet C; Renard N; Neidhardt-Berard EM; Coiffier B
    J Clin Oncol; 1997 Feb; 15(2):499-508. PubMed ID: 9053471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of suppressor of cytokines signalling-3 mRNA expression from patients with non-Hodgkin lymphoma under chemotherapy.
    Attia FM; Hassan AM; El-Maraghy NN; Ibrahium GH
    Cancer Biomark; 2011-2012; 11(1):41-7. PubMed ID: 22820139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of some inflammatory markers in patients with lymphoma.
    Hamed Anber N; El-Sebaie AH; Darwish NHE; Mousa SA; Shamaa SS
    Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30814315
    [No Abstract]   [Full Text] [Related]  

  • 16. Lactate dehydrogenase 5 expression in Non-Hodgkin lymphoma is associated with the induced hypoxia regulated protein and poor prognosis.
    Lu R; Jiang M; Chen Z; Xu X; Hu H; Zhao X; Gao X; Guo L
    PLoS One; 2013; 8(9):e74853. PubMed ID: 24086384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of interleukin-6 and interleukin-10 in Turkish patients with aggressive non-Hodgkin's lymphoma.
    Guney N; Soydinc HO; Basaran M; Bavbek S; Derin D; Camlica H; Yasasever V; Topuz E
    Asian Pac J Cancer Prev; 2009; 10(4):669-74. PubMed ID: 19827892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble CD44 and CD44v6 and prognosis in children with B-cell acute lymphoblastic leukemia.
    Amirghofran Z; Asiaee E; Kamazani FM
    Asia Pac J Clin Oncol; 2016 Sep; 12(3):e375-82. PubMed ID: 25227983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating CD44 and intercellular adhesion molecule-1 levels in low grade non-hodgkin lymphoma and B-cell chronic lymphocytic leukemia patients during interferon-alpha-2a treatment.
    Beksaç M; Arat M; Akan H; Koç H; Ilhan O; Ozcan M
    Cancer; 2000 Oct; 89(7):1474-81. PubMed ID: 11013360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epiregulin: A new prognostic molecule in non-Hodgkin lymphoma.
    Demir I; Akan OY; Bilgir F; Yilmaz I; Bozkaya G; Bilgir O
    Ir J Med Sci; 2024 Jun; 193(3):1201-1207. PubMed ID: 38270775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.